Scarica l'app Stockscreener
9.86
4.55%
-0.47
Dopo l'orario di chiusura:
9.86
Quoin Pharmaceuticals Ltd Adr Borsa (QNRX) Ultime notizie
Zoetis (NYSE:ZTS) & Quoin Pharmaceuticals (NASDAQ:QNRX) Head to Head Survey - Defense World
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - The Manila Times
Quoin Pharmaceuticals stock rises after positive pediatric trial data - Investing.com
Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause - MSN
Quoin Pharmaceuticals announces FDA granted ODD to QRX003 - TipRanks
Quoin Pharmaceuticals Ltd – ADR trading resumes - MSN
Quoin Pharmaceuticals director Langer buys $128,640 in ADSs - Investing.com
Quoin Pharmaceuticals, Ltd.American Depositary Shares (Nasdaq:QNRX) Stock Quote | Pittsburgh Post-Gazette - FinancialContent
Quoin Pharmaceuticals (NASDAQ:QNRX) Receives Sell (E) Rating from Weiss Ratings - Defense World
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Why NioCorp Developments Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - inkl
Quoin Pharmaceuticals (QNRX) Stock Is Skyrocketing Friday: What's Going On? - Benzinga
Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com
Quoin Pharmaceuticals secures up to $104.5 million in private placement - Investing.com
What's Going On With Serve Robotics Shares Friday? - inkl
Quoin Pharmaceuticals. Ltd Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Quoin Pharmaceuticals finalizes separation agreement with former CFO - Investing.com
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Up 2.8% – Still a Buy? - Defense World
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
Quoin (QNRX) Q2 Loss Beats Estimates - The Motley Fool
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - The Globe and Mail
Quoin Pharmaceuticals stock rises after positive clinical updates - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials - Investing.com India
Quoin Pharmaceuticals advances rare disease pipeline with two active trials By Investing.com - Investing.com Nigeria
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Price Down 2.9% – Here’s Why - Defense World
MINISO Group Holding Limited Unsponsored ADR (NYSE:MNSO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Quoin Pharmaceuticals CFO Gordon Dunn to depart following mutual agreement - Investing.com India
Quoin Pharmaceuticals (NASDAQ:QNRX) Trading Down 1.2% – Should You Sell? - Defense World
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
FDA grants rare pediatric disease designation for Netherton syndrome drug - Investing.com
Quoin announces FDA clearance to initiate second whole body QRX003 NS study - TipRanks
FDA clears Quoin’s new Netherton syndrome study By Investing.com - Investing.com South Africa
FDA clears Quoin’s new Netherton syndrome study - Investing.com
Quoin Pharmaceuticals announces EMA grants ODD for QRX003 - TipRanks
Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data By Stocktwits - Investing.com India
Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday - Benzinga
Quoin Pharmaceuticals announces initial positive clinical data for QRX003 - TipRanks
Quoin reports progress in pediatric skin disorder study By Investing.com - Investing.com India
Quoin Pharmaceuticals reports Q1 EPS ($6.50) vs ($38.73) last year - TipRanks
Quoin Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com India
Quoin Pharmaceuticals regains compliance with Nasdaq minimum bid price rule - TipRanks
Quoin Pharmaceuticals regains Nasdaq compliance with bid price - Investing.com
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - The Globe and Mail
Quoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirements - Investing.com
Quoin Pharmaceuticals reports positive clinical data for rare disease treatment - Investing.com
QNRX Stock Plummets to 52-Week Low at $0.26 Amid Market Struggles - Investing.com
Quoin seeks patent for skin disease treatment QRX003 - Investing.com
Quoin Pharmaceuticals reports promising Netherton Syndrome treatment - Investing.com
Quoin Pharmaceuticals launches Netherton awareness campaign - Investing.com
Quoin reports positive results in Netherton Syndrome study - Investing.com
Quoin Pharmaceuticals CEO Michael Myers acquires $250,000 in shares - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com
Quoin Pharmaceuticals COO acquires $28,737 in company shares - Investing.com
Quoin Pharmaceuticals (QNRX) Stock Trends and Sentiment 2025 - MarketBeat
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):